Allspring Global Investments Holdings LLC Grows Stake in Phibro Animal Health Corporation $PAHC

Allspring Global Investments Holdings LLC boosted its position in Phibro Animal Health Corporation (NASDAQ:PAHC) by 145.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 286,172 shares of the company’s stock after purchasing an additional 169,628 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Phibro Animal Health were worth $15,671,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in PAHC. 1620 Investment Advisors Inc. lifted its holdings in Phibro Animal Health by 77.4% during the fourth quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company’s stock valued at $25,000 after purchasing an additional 295 shares during the last quarter. Farther Finance Advisors LLC increased its position in shares of Phibro Animal Health by 113.2% during the fourth quarter. Farther Finance Advisors LLC now owns 727 shares of the company’s stock valued at $27,000 after buying an additional 386 shares during the period. Rothschild Investment LLC grew its position in Phibro Animal Health by 2,500.0% during the fourth quarter. Rothschild Investment LLC now owns 1,040 shares of the company’s stock worth $39,000 after buying an additional 1,000 shares in the last quarter. iSAM Funds UK Ltd bought a new position in shares of Phibro Animal Health in the 3rd quarter worth $61,000. Finally, EverSource Wealth Advisors LLC raised its position in shares of Phibro Animal Health by 7,671.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,720 shares of the company’s stock valued at $69,000 after buying an additional 2,685 shares in the last quarter. 99.34% of the stock is currently owned by institutional investors.

Phibro Animal Health Trading Up 2.5%

NASDAQ:PAHC opened at $33.86 on Wednesday. The firm has a market capitalization of $1.37 billion, a P/E ratio of 14.53, a P/E/G ratio of 0.46 and a beta of 0.46. The company has a quick ratio of 1.26, a current ratio of 3.17 and a debt-to-equity ratio of 1.97. The company has a fifty day moving average of $32.53 and a 200 day moving average of $43.37. Phibro Animal Health Corporation has a 52 week low of $25.58 and a 52 week high of $60.08.

Phibro Animal Health (NASDAQ:PAHC) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.76 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.04. The firm had revenue of $383.54 million for the quarter, compared to analysts’ expectations of $367.02 million. Phibro Animal Health had a net margin of 6.35% and a return on equity of 37.14%. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. On average, research analysts predict that Phibro Animal Health Corporation will post 3.08 earnings per share for the current year.

Phibro Animal Health Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, June 24th. Investors of record on Wednesday, June 3rd were issued a $0.12 dividend. The ex-dividend date was Wednesday, June 3rd. This represents a $0.48 annualized dividend and a yield of 1.4%. Phibro Animal Health’s payout ratio is 20.60%.

Analysts Set New Price Targets

PAHC has been the topic of a number of research analyst reports. Citigroup reduced their target price on Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating on the stock in a research note on Thursday, May 14th. Weiss Ratings cut Phibro Animal Health from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, June 15th. Zacks Research downgraded Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 21st. Finally, Wall Street Zen lowered shares of Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. One research analyst has rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Phibro Animal Health has a consensus rating of “Hold” and a consensus target price of $42.50.

Insider Transactions at Phibro Animal Health

In other Phibro Animal Health news, CEO Jack Bendheim sold 7,040 shares of the business’s stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $55.80, for a total transaction of $392,832.00. Following the transaction, the chief executive officer directly owned 67,720 shares of the company’s stock, valued at approximately $3,778,776. The trade was a 9.42% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 25,648 shares of company stock worth $1,377,432. 50.13% of the stock is currently owned by insiders.

Phibro Animal Health Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.